{"id":"W2907355714","doi":"10.1182/blood-2018-99-119201","title":"Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); Regimen; Myelofibrosis; Internal medicine; Interleukin-3 receptor; Clinical trial; Oncology; Cohort; Malignancy; Stage (stratigraphy); Gastroenterology; Myeloid; Bone marrow; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003402288,0.001299419,0.001444695,0.0002826233,0.0004296193,0.000806384,0.0006753692,0.001195572,0.003074136],"category_scores_gemma":[0.001107333,0.0003602624,0.001154452,0.0002722195,0.000637474,0.0008461205,0.0002676305,0.002571964,0.0007595312],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007647714,"about_ca_system_score_gemma":0.001389169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007875193,"about_ca_topic_score_gemma":0.002045695,"domain_scores_codex":[0.9994011,0.0003064785,0.00004008417,0.00008048874,0.00005954103,0.0001123892],"domain_scores_gemma":[0.9990687,0.0001912373,0.0001716771,0.00008933712,0.00008727769,0.0003918717],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6720768,0.08363816,0.01865911,0.0009439696,0.002127878,0.0004889963,0.0005062784,0.003901131,0.06349328,0.0003157312,0.009434085,0.1444146],"study_design_scores_gemma":[0.4334023,0.5240582,0.02942418,0.00005801635,0.0008616965,0.0004375466,0.00006548558,0.001185069,0.005802358,0.0002860837,0.004383048,0.00003610447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891024,0.001793482,0.0007974083,0.0006225539,0.00007393564,0.002886796,0.002581063,0.0001138219,0.002028469],"genre_scores_gemma":[0.9803705,0.001401407,0.002813583,0.001114887,0.000166942,0.003705704,0.007815985,0.00003312401,0.002577879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003402288,"threshold_uncertainty_score":0.01799327,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02825834787298184,"score_gpt":0.3189661243057327,"score_spread":0.2907077764327509,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}